Supplemental Figure S4 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

• DOI: 10.1158/1078-0432.22473416.v1
• Publication Date: 2023-04-01T14:31:29Z
• Authors: Julia K. Rotow; Philippe Gui; Wei Wu; Victoria M. Raymond; Richard B. Lanman; Frederic J. Kaye; Nir Peled; Ferran Fece de la...; Brandon Nadres; Ryan B. Corcoran; Iwei Yeh; Boris C. Bastian; Petr Starostik; Kimberly Newsom; Victor R. Olivas; Alexander M. Wolff; James S. Fraser; Eric A. Collisson; Caroline E. McCoach; D. Ross Camidge; Jose Pacheco; Lyudmila Bazhenova; Tianhong Li; Trever G. Bivona; Collin M. Blakely

<p>KRAS amplification and/or KRAS G12D mutation in METex14-mutated NSCLC with resistance to crizotinib</p>